Prostaglandins, such as prostaglandin (PG)E~2~,^1^ are pivotal modulators of tissue homeostatsis and their aberrant regulation is known to cause serious pathophysiological consequences ([@B1]--[@B4]). PGE~2~ biosynthesis is regulated by successive metabolic steps involving the phospholipase A~2~-- mediated release of arachidonic acid (AA) and its conversion to PGE~2~ by cyclooxygenase (COX), hydroperoxidase, and isomerase activities ([@B1]--[@B4]). Although cytosolic phospholipase A~2~ (cPLA~2~) is primarily responsible for agonist-induced AA release from membrane phospholipids ([@B5], [@B6]), secretory PLA~2~ may also be important in regulating AA availability via a transcellular mechanism ([@B7]). Conversion of AA to PGH~2~, the commited step in prostanoid biosynthesis, is mediated by cyclooxygenases, COX-1 and -2, which are encoded by two unique genes, located on different chromosomes ([@B2]). Generally, although COX-1 is constitutively expressed, the expression of COX-2 is highly inducible ([@B2], [@B3]). Based on their respective modes of expression, it is thought that COX-1 is primarily involved in cellular homeostasis, whereas COX-2 plays a major role in inflammation and mitogenesis. The COX isoenzymes are thought to be the primary target enzymes for nonsteroidal antiinflammatory drugs (NSAIDs), which act by inhibiting the COX activity of COX-1 and -2, thereby blocking their ability to convert AA to PGG~2~ ([@B8], [@B9]). In addition to the use of nonsteroidal antiinflammatory drugs as analgesics and for alleviation of acute and chronic inflammation, these agents have proven effective in decreasing the frequency of heart attacks and strokes ([@B8], [@B10], [@B11]), and in reducing the incidence of colon cancer ([@B12], [@B13]).

Since most cells invariably express both COX-1 and -2 under the appropriate conditions, it has been somewhat problematic to determine the exact contribution of the two COX isozymes towards basal and agonist-inducible PGE~2~ biosynthesis; the use of selective COX-1/COX-2 inhibitors to define relative contributions of the two isozymes has also resulted in limited success. The purpose of this study was to examine the effects of COX deficiency on the differential expression of the COX-1 and -2 isozymes, and compare the responses of wild-type, COX-1, and COX-2 knockout cells with respect to agonist-induced PGE~2~ biosynthesis. We demonstrate that the expression of COX, cPLA~2~, and PGE~2~ production are significantly increased in COX-deficient cells. Thus, COX deficiency, regardless of whether it is COX-1 or -2, results in the enhanced basal and inducible expression of the remaining COX isozyme as well as the elevated expression of cPLA~2~. We interpret these data to indicate that the elevated production of PGE~2~ in COX-1 or -2 isozyme-deficient cells is due to the compensatory expression of the remaining COX isozyme.

Materials and Methods {#MaterialsMethods}
=====================

Isolation and Culture of COX-deficient Mouse Cells.
---------------------------------------------------

Lungs were collected from wild-type C57BL/6J (B6), COX-1--deficient ([@B14]), and COX-2--deficient ([@B15]) mice. The tissues were dissected into small pieces and grown underneath coverslips in 10-cm plates with MEM supplemented with PenStrep at a concentration of 300,000 U/liter penicillin G and 300 mg/liter streptomycin sulfate, nonessential amino acids (0.1 mM), Fungizone (1 mg/liter Amphotericin B), glutamine (292 mg/liter), ascorbic acid (50 mg/ liter), and 10% FCS in a humidified incubator with 5% CO~2~, and the media were changed three times per week. After 3 wk of culture under these conditions, only fibroblasts continued to grow. The PenStrep was reduced to 100,000 U/liter penicillin G and 100 mg/liter streptomycin sulfate and the media were replaced twice per week for another 3--5 wk. During subsequent passages, cells were maintained in DMEM containing high glucose and supplemented with PenStrep (100,000 U/liter penicillin G and 100 mg/liter streptomycin sulfate), nonessential amino acids (0.1 mM), Fungizone (1 mg/liter Amphotericin B), glutamine (292 mg/liter), ascorbic acid (50 mg/liter), and 10% FCS.

Transfection/Immortalization of COX-deficient Cells.
----------------------------------------------------

Subconfluent monolayers of COX-1^−/−^ or COX-2^−/−^ lung fibroblasts (passages 5--7) were cotransfected with pLE12S (containing adenovirus E1A gene; 8 μg/10-cm diam dish) and pREP4 (containing a hygromycin resistance gene; Invitrogen, Carlsbad, CA) plasmids (2 μg/10-cm diam dish) by the LipofectAMINE reagent (GIBCO BRL, Gaithersburg, MD). Plasmid pLE12S was a gift of Dr. Margaret Quinlan (University of Tennessee, Memphis, TN). Cells were maintained in the above media containing hygromycin (50 μg/ml) for 1 wk; hygromycin in the culture media was increased 50 μg/ml per week until the final concentration reached 250 μg/ml. Subsequent cell passage and subculture of cells used in all experiments was done in media containing 250 μg/ml hygromycin.

Treatment of COX-1^−^ ^/−^ and COX-2^−^ ^/−^ Cells with Cytokines and PMA.
--------------------------------------------------------------------------

Cells were seeded at 10^5^ cells/ml in DMEM (high glucose) supplemented with PenStrep (100,000 U/liter penicillin G and 100 mg/liter streptomycin sulfate), nonessential amino acids (0.1 mM), Fungizone (1 mg/liter Amphotericin B), glutamine (292 mg/liter), ascorbic acid (50 mg/liter), 10% FCS, and 250 μg/ml hygromycin in 24-well (0.9 ml/well) flat-bottomed tissue culture plates (Costar, Cambridge, MA). Cells were incubated at 37°C in a humidified CO~2~ incubator (5% CO~2~) for 48 h until confluent. The medium was then replaced with fresh DMEM containing 0.5% FCS. Where indicated, cells were treated with IL-1 (0.25 ng/ml), TNF (5 ng/ml), acidic fibroblast growth factor (FGF; 10 ng/ml), or PMA (12.5 ng/ml) along with the appropriate vehicle controls; at these concentrations, neither cytokines nor PMA affected cell morphology or viability. In Western blot experiments, cells were treated as above except they were seeded in 6-well culture plates (2.7 × 10^5^ cells/well).

Western Blot Analysis.
----------------------

The medium from COX-deficient cells cultured in 6-well plates was aspirated and cell monolayers were washed with cold PBS and lysed in the Laemmli sample buffer. The samples were boiled for 3 min, and identical amounts of protein applied to SDS-PAGE (7.5%) and later transblotted to an Optitran membrane (Schleicher & Schuell, Keene, NH). The blot was blocked with 5% nonfat dry milk before incubation with either a rabbit antibody against murine COX-2 (Cayman Chemical, Ann Arbor, MI), a rabbit antibody against murine COX-1 (provided by Dr. D. DeWitt; reference [@B16]), or mouse monoclonal anti-cPLA~2~ antiserum (Santa Cruz Biotechnology, Santa Cruz, CA). Proteins were detected using either enhanced chemiluminescence or enhanced chemifluorescence kits from Amersham Corp. (Arlington Heights, IL).

PGE~2~ Measurement.
-------------------

PGE~2~ in the media was measured by radioimmunoassay (RIA); this assay is based upon the competition by PGE~2~ in the test sample with labeled PGE~2~ for anti-PGE~2~ antibody binding sites. A 2--100-μl aliquot of culture medium was added to RIA assay buffer (0.1 mM phosphate buffer, pH 7.4, containing 0.9% sodium chloride, 0.1% sodium azide, and 0.1% gelatin), and mixed with the appropriate amount of labeled tracer and reconstituted antiserum. The mixture was incubated overnight at 4°C. Assay tubes were then placed in an ice bath, and 1 ml of cold charcoal-dextran suspension was added. After a 15-min incubation, the tubes were centrifuged at 2,200 *g* for 10 min at 4°C; the supernatants were decanted into scintillation vials, and radioactivity was determined by scintillation spectrometry. Percent binding was compared against a standard curve, and the amount of PGE~2~ in the sample was calculated. In each case the amount of PGE~2~ produced was normalized by cell number and all data is presented as picograms of PGE~2~ per 10^3^ cells. To determine the potential effect of nonenzymatically produced, PGE~2~-immunoreactive products (e.g., isoprostanes) on RIA results, assays were performed in the presence of an effective COX-1 inhibitor (indomethacin, 1 mM) and NS-398 (1 μM), a COX-2 inhibitor, both of which block PGE~2~ biosynthesis, but should not block the production of nonenzymatically generated AA metabolites; products were further analyzed by radio-thin-layer chromatography ([@B17]).

Statistical Analysis.
---------------------

Paired *t* test was used to determine the differences in the PGE~2~ levels between control samples of wild-type, COX-1^−/−^ and COX-2^−/−^ cells, and between control samples and samples from cytokine-treated cells. Differences were considered significant if *P* \<0.05.

Results and Discussion {#ResultsDiscussion}
======================

We examined the effects of IL-1 on PGE~2~ production in cells containing both COX isozymes (wild type) compared with cells that had only COX-1 (COX-2^−/−^) or COX-2 (COX-1^−/−^), respectively. As shown in Fig. [1](#F1){ref-type="fig"} *A* both COX-1^−/−^ or COX-2^−/−^ cells synthesized 6--8-fold higher amounts of PGE~2~ compared with their wild-type counterparts. Interestingly, basal PGE~2~ production was higher in both COX-2^−/−^ (66.71 ± 3.54 pg/10^3^ cells; *n* = 6) and COX-1^−/−^ (90.23 ± 3.29 pg/10^3^ cells; *n* = 8) cells compared with wild-type (11.07 ± 0.62 pg/10^3^ cells; *n* = 8). (All values are mean ± SE.) IL-1 treatment of wild-type and COX-1^−/−^ cells further enhanced their PGE~2~ output. In contrast, IL-1 treatment of COX-2^−/−^ cells did not significantly enhance PGE~2~ biosynthesis (Fig. [1](#F1){ref-type="fig"} *A*).

These dramatic differences in basal PGE~2~ biosynthesis between wild-type and COX-deficient cells, prompted us to compare the expression of genes encoding three key enzymes (COX-1, COX-2, and cPLA~2~) regulating PGE~2~ biosynthesis in untreated and IL-1--treated wild-type, COX-1^−/−^, and COX-2^−/−^ cells. A comparison of basal and IL-1-- stimulated levels of COX-1 and COX-2 protein by immunoblot assay in wild-type and COX-1^−/−^ cells is shown in Fig. [1](#F1){ref-type="fig"}, *B* and *C.* Consistent with numerous previous observations, the basal expression of COX-2 protein in wild-type cells was barely detectable (Fig. [1](#F1){ref-type="fig"} *B*). Constitutive levels of COX-2 proteins were also significantly increased (2.4-fold) in untreated COX-1^−/−^ cells (Fig. [1](#F1){ref-type="fig"} *B*). The elevated level of COX-2 protein correlates well with the higher basal PGE~2~ levels in COX-1^−/−^ cells compared with those in wild-type cells. When treated with IL-1, COX-2 protein levels increased moderately in wild-type cells (Fig. [1](#F1){ref-type="fig"} *B*), but the increase in COX-2 protein was much more dramatic in COX-1^−/−^ cells (41-fold). The overall pattern of COX-2 protein expression in wild-type and COX-1^−/−^ cells correlated with increased PGE~2~ production seen in cells with unique COX phenotypes (see Fig. [1](#F1){ref-type="fig"} *A*).

Next, we examined the basal and IL-1--stimulated levels of COX-1 protein in identically treated wild-type, COX-2^−/−^, and COX-1^−/−^ cells, respectively (Fig. [1](#F1){ref-type="fig"} *C*). In wild-type cell extracts, the level of COX-1 protein was barely detectable and IL-1 treatment was apparently inconsequential. This result was not unexpected since COX-1 expression is not known to be inducible under many conditions. We observed that basal expression of COX-1 protein in untreated COX-2^−/−^ cells (Fig. [1](#F1){ref-type="fig"} *C*) was much greater (14-fold) than that in wild-type cells. This overexpression of COX-1 protein corresponds with greater basal PGE~2~ levels in COX-2^−/−^ cells, compared with the basal levels in wild-type cells. IL-1 had no stimulatory effect on COX-1 protein levels in COX-2^−/−^ cells (Fig. [1](#F1){ref-type="fig"} *C*) and as expected, COX-1^−/−^ cells did not express detectable COX-1 protein. Another important enzyme in the prostaglandin biosynthetic pathway is PGE~2~ synthase, the isomerase that converts PGH~2~ to PGE~2~. Although PGE~2~ synthase has neither been sequenced nor cloned, making it difficult to study, available evidence does seem to indicate that this enzyme is not a rate-limiting reaction in PGE~2~ biosynthesis. However, based upon our findings, we cannot rule out the possibility that PGE~2~ synthase expression may also be altered in COX null cells.

To examine the possibility that iso-PGE~2~ or other isoprostanes ([@B18]) may be generated nonenzymatically from a buildup of endoperoxide intermediate that cross-reacts with the anti-PGE~2~ used in our RIA leading to erroneously high estimations of COX and/or PGE~2~ synthase activity, we performed two experiments. First, we treated wild-type and COX^−/−^ cells with either indomethacin or NS-398, COX-1, and COX-2 selective inhibitors, respectively since these COX inhibitors should block PGE~2~ synthesis without affecting iso-PGE~2~ formation. We found that either indomethacin or NS-398 completely blocked both the basal and cytokine-induced formation of immunoreactive PGE~2~ in wild-type and COX^−/−^ cells (data not shown). Second, radio-thin-layer chromatography was used to confirm that PGE~2~ was by far the predominate prostanoid product generated by wild-type and COX^−/−^ cells and that no other AA metabolites in addition to PGE~2~ were generated in COX^−/−^ cells (data not shown).

To compare the effects of IL-1 (see Fig. [1](#F1){ref-type="fig"} *A*) to other inducers of PGE~2~ biosynthesis, we tested the effects of TNF, acidic FGF, and PMA on PGE~2~ production in wild-type, COX-2^−/−^, and COX-1^−/−^ cells (Fig. [2](#F2){ref-type="fig"}). Compared to stimulated wild-type cells, there was significantly more PGE~2~ produced in either COX-1^−/−^ or COX-2^−/−^ cells, with the possible exception of TNF that induced comparable PGE~2~ biosynthesis in each cell type. In response to FGF, the amount of PGE~2~ that was produced by COX-2^−/−^ cells was elevated and in COX-1^−/−^ cells, PGE~2~ was even more dramatically elevated compared to wild type. Both COX-2^−/−^ and COX-1^−/−^ cells treated with PMA also produced much more PGE~2~ than wild type. Thus, in general, COX-isozyme deficiency results in increased PGE~2~ biosynthesis, but the relative contributions of COX-1 and COX-2 are clearly dependent upon the specific agonists involved.

Since constitutive COX-2 protein expression and PGE~2~ production in COX-1^−/−^ cells was significantly enhanced, we were also curious about the status of cPLA~2~ gene expression in COX-deficient cells. We reasoned that cPLA~2~ activity could be involved in regulating levels of free AA for conversion to PGE~2~ and thereby could play a critical role in compensating for COX-isozyme deficiency. We were somewhat surprised to find that basal levels of cPLA~2~ protein in either COX-2^−/−^ (Fig. [3](#F3){ref-type="fig"} *B*) or COX-1^−/−^ (Fig. [3](#F3){ref-type="fig"} *C*) cells were significantly higher than levels of cPLA~2~ in wild-type cells (Fig. [3](#F3){ref-type="fig"} *A*). It is conceivable, therefore, that enhanced expression of cPLA~2~ could directly contribute to higher PGE~2~ levels in both of the COX-deficient cells by generating greater AA substrate for PGE~2~ biosynthesis. Treatment of COX-1^−/−^ or COX-2^−/−^ cells with IL-1 resulted in a modest increase in the amount of cPLA~2~ protein (4-fold in COX-1^−/−^ and 1.4-fold in COX-2^−/−^). This was in contrast to wild-type cells, which showed no change in the levels of cPLA~2~ protein after treatment with IL-1. As an important control, we examined the quantitative parameters of PGE~2~ production, and COX-1, COX-2, and cPLA~2~ gene expression in wild-type, COX-2^−/−^, and COX-1^−/−^ cells from primary cell cultures and found essentially the same patterns in primary cells as those observed in the immortalized cells (data not shown). Therefore, the characteristic pattern of expression of COX-1, COX-2, and cPLA~2~ proteins in COX-2^−/−^ and COX-1^−/−^ cells is not elicited as a result of immortalization caused by the E1A adenovirus gene. Taken together these data indicate that COX-1^−/−^ cells express enhanced levels of both basal and cytokine-stimulated COX-2 protein, and increased basal expression of cPLA~2~ protein. We postulate that the significantly increased levels of COX-2 and cPLA~2~ in COX-1^−/−^ cells are likely to account for the increased rates of PGE~2~ biosynthesis; these data also implicate the existence of compensatory mechanisms for PGE~2~ production in COX-isozyme--deficient cells.

To distinguish between preferences of COX-1 and -2 for endogenous and/or exogenous AA for conversion to PGE~2~, and to verify that COX-1 was indeed expressed in COX-2^−/−^ cells as judged by its ability to synthesize PGE~2~, we added exogenous AA to wild-type, COX-2^−/−^, or COX-1^−/−^ cells that were either untreated or treated with IL-1, TNF, FGF, or PMA. The results shown in Fig. [4](#F4){ref-type="fig"} demonstrate that cells expressing only COX-1 (COX-2^−/−^) synthesized similar amounts of PGE~2~ as wild-type or COX-1^−/−^ cells supplemented with exogenous AA. Therefore, COX-1 is expressed and enzymatically active in COX-2^−/−^ cells, but cytokines neither enhance COX-1 protein biosynthesis nor PGE~2~ biosynthesis. Thus, agonists that induce PGE~2~ biosynthesis in COX-2^−/−^ cells in the absence of exogenous AA, do so by increasing endogenous substrate availability. Based on these data, we conclude that in COX-2^−/−^ cells, substrate is likely to be limiting for constitutively expressed COX-1--mediated PGE~2~ biosynthesis. Fig. [4](#F4){ref-type="fig"} also shows that COX-1^−/−^ cells are able to use both exogenous and endogenous substrates (also see Fig. [1](#F1){ref-type="fig"} *A*). However, IL-1, TNF, and FGF significantly enhanced the ability of COX-1^−/−^ cells to produce PGE~2~, most likely by enhancing COX-2 expression as shown in Fig. [2](#F2){ref-type="fig"}. In addition, COX-1^−/−^ cells treated with PMA did not produce elevated levels of PGE~2~, even when exogenous AA was provided. This indicates that PMA likely increased PGE~2~ production by increasing the availability of endogenous AA in COX-1^−/−^ cells, whereas IL-1, TNF, and FGF likely affect AA mobilization and COX-2 expression. PMA affected the wild-type cells similarly. These results clearly raise the possibility that in COX-1 or -2 null cells, there is a coordinate upregulation of the expression and/or activities of COX-1, COX-2, and cPLA~2~, leading to increased PGE~2~ biosynthesis. These data also demonstrate that both COX-1^−/−^ and COX-2^−/−^ cells can effectively use AAs from either endogenous or exogenous sources.

Our data are consistent with the hypothesis that the long-term of COX-isozyme deficiency results in the altered expression of the remaining two enzymes that regulate mobilization and conversion of arachidonic acid to prostaglandins. Fig. [5](#F5){ref-type="fig"} summarizes the patterns of COX and cPLA~2~ expression in COX null cells compared with normal cells in response to IL-1. The scheme shows the compensatory expression of the alternative COX isozyme and cPLA~2~ when one of the COX isozymes is absent. In cells lacking the housekeeping isozyme COX-1, overcompensation results in the overexpression of COX-2 and cPLA~2~, and in turn elevated PG biosynthesis. Similarly, cells lacking the inducible isozyme, COX-2, elicit the enhanced expression of COX-1 and cPLA~2~. Although we are uanble to comment as to the precise status of PGE~2~ synthase expression in wild-type, COX-1^−/−^ or COX-2^−/−^ cells, we have depicted its expression in each cell type; since PGE~2~ is the predominate prostanoid product, its expression would not appear to be rate-limiting given the great potential for PGE~2~ biosynthesis in the presence of exogenous AAs (see Fig. [4](#F4){ref-type="fig"}). Thus, our data clearly show that COX-deficient cells have the potential to overcome the lack of expression of one or the other COX isoenzymes by overexpressing the alternate COX isoform and increased cPLA~2~ expression. Such a potential mechanism for producing PGE~2~ by cells in vitro is not surprising since neither COX-1^−/−^ ([@B14]) nor COX-2^−/−^ mice ([@B15]) showed severe developmental arrest in utero or immediate postnatal mortality. However, in contrast to the results shown here using lung fibroblasts, Langenbach et al. ([@B14]) did not report any compensatory COX-2--mediated PGE~2~ production in glandular stomachs of COX-1--deficient mice, suggesting that tissue specificity may also be an important factor for further investigation. Together, these findings underscore the importance of elucidating the potential long-term effects of COX-1 or COX-2 inhibition with respect to alterations in the quantitiative and/or qualitative patterns of AA metabolism.
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![The effect of IL-1 on PGE~2~ biosynthesis, COX-1, and -2 expression. (*A*) Wild-type, COX-2^−/−^, and COX-1^−/−^ cells were treated with vehicle (*Control*) or with IL-1 (0.25 ng/ ml) as described in Materials and Methods. After 24 h of culture, media was collected and analyzed for PGE~2~ by RIA. Data are means ± SE of at least six separate determinations (wells). ^‡^ Values that are significantly different from the wild-type value in the control group by paired *t* test (*P* \<0.05). \* Values that are significantly different from the control values of each respective cell type by paired *t* test. (*B*) Western blot analysis of COX-2 protein levels in IL-1--stimulated cells. Wild-type, COX-2^−/−^, and COX-1^−/−^ cells were treated with vehicle (*Control*) or with IL-1 (0.25 ng/ml) as described in Materials and Methods. After 24 h of culture, media was removed and Western blot analysis was carried out as described in Materials and Methods. (*C*) Western blot analysis of COX-1 protein levels in IL-1--stimulated cells. Wild-type, COX-2^−/−^, and COX-1^−/−^ cells were treated with vehicle (*Control*) or with IL-1 (0.25 ng/ml) as described in Materials and Methods. After 24 h of culture, media was removed and Western blot analysis was carried out as described in Materials and Methods.](JEM971680.f1){#F1}

![The effect of cytokines and PMA on PGE~2~ biosynthesis. Wild-type (*A*), COX-2^−/−^ (*B*), and COX-1^−/−^ (*C*) mouse cells were treated with IL-1 (0.25 ng/ml), TNF (5 ng/ml), FGF (10 ng/ml), or PMA (12.5 ng/ml) as described in Materials and Methods. After 24 h of culture, media was collected and analyzed for PGE~2~ by RIA. Data are means ± SE of at least six separate determinations (wells). \* Values that are significantly different from the control values of each respective cell type by paired *t* test (*P* \<0.05).](JEM971680.f2){#F2}

![Expression of cPLA~2~ in IL-1--stimulated cells. Wild-type, COX-2^−/−^, and COX-1^−/−^ mouse cells were treated with vehicle (*Control*) or with IL-1 (0.25 ng/ml) as described in Materials and Methods. After 24 h of culture, media was removed and Western blot analysis was carried out as described in Materials and Methods. (*A*) Proteins from wild-type cells. (*B*) Proteins from COX-2^−/−^ cells. (*C*) Proteins from COX-1^−/−^ cells. *A*, *B*, and *C* are from the same blot, which is a representative of three replications.](JEM971680.f3){#F3}

![The effect of exogenous arachidonic acid on cytokines or PMA induced PGE~2~ production. Wild-type (*A*), COX-2^−/−^ (*B*), and COX-1^−/−^ (*C*) mouse cells were treated with IL-1 (0.25 ng/ml), TNF (5 ng/ml), FGF (10 ng/ml), or PMA (12.5 ng/ml) as described in Materials and Methods. After 24 h of culture, media was removed, the cells were washed to remove any accumulated PGE~2~, and fresh serum-free media containing AA (50 μM) was added. After a 15-min incubation in the presence of added AA, media was collected and PGE~2~ measured by RIA. Data are means ± SE of at least six separate determinations (wells). \* Values that are significantly different from the control values of each respective cell type by paired *t* test (*P* \<0.05).](JEM971680.f4){#F4}

![The coordinate regulation of COX-1, COX-2, and cPLA~2~ expression in COX null cells by IL-1. In wild-type cells, inducible COX-2 is responsible for the increase in IL-1--induced PGE~2~ production as represented by proportionally larger characters and lines throughout the diagram. Although the constitutive level of COX-1 expression is low, exogenous AA (*exo. AA*) is effectively converted to PGE~2~. In COX-2^−/−^ or COX-1^−/−^ cells, the overexpression of cPLA~2~ may play a role in increased basal PGE~2~ biosynthesis compared to wild-type cells by increasing the availability of endogenous AA (*endo. AA*). IL-1 greatly induces COX-2 accumulation in COX-1^−/−^ cells resulting in enhanced PGE~2~ biosynthesis. In COX-2^−/−^ cells, overexpression of COX-1 and cPLA~2~ lead to an increase in basal PGE~2~ biosynthesis compared to wild type. However, IL-1 does not enhance PGE~2~ biosynthesis in COX-2^−/−^ due to the lack of increased COX-1 expression. As in wild-type cells, exogenous AA is effectively used by COX-1 in COX-2^−/−^ cells as indicated by a high level of PGE~2~ accumulation. At present, the effects of COX-isozyme deficiency on the expression of PGE~2~ synthase are not known, but this enzyme does not appear to be rate limiting.](JEM971680.f5){#F5}
